Impilo AB, the Nordic investment company focused on healthcare investments, has secured new commitments from new and existing investors of SEK 6bn (EUR 590m) and significantly exceeding its target amount. The capital raised enables new platform investments and follow-on investments in existing portfolio companies. In combination with the value of the current portfolio, Impilo’s total assets under management now exceed SEK 10bn (EUR 980m).
Read moreNews
Impilo’s portfolio company Decon acquires Acekare – a French-based manufacturer and distributor of mobility assistance solutions
The acquisition of Acekare marks an important step in Decon’s strategic ambition to build a leading European niche mobility platform by adding a complementary product company to its existing offering and establishing a direct presence in the French market
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo completes the acquisition of Oticon Medical
We are pleased to announce that Impilo has today completed the acquisition of Oticon Medical from Demant A/S. This marks the first investment in our recently raised Fund II.